Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
These are the stocks posting the largest moves midday.Market Insiderread more
The red-hot market for new public companies in 2019 like Beyond Meat and Chewy could spell bad news for the stock market, Bernstein says.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
It's about time to write off high-growth tech stocks, Goldman warns, saying software carries the highest multiples since the tech bubble.Marketsread more
Profits for major U.S. tobacco companies could be cut in half if the FDA adopts a "maximum nicotine" rule within the next 15 years, according to analysts at Morgan Stanley.Tobaccoread more
Mursi, a top figure in the now-banned Muslim Brotherhood, had been in jail since being toppled by the military in 2013 after barely a year in power following mass protests...World Politicsread more
Drug companies need better ways to recruit patients for their clinical trials, an undertaking that costs millions of dollars today.
Dozens of technology start-ups have popped up to solve this problem.
One start-up in this group is Antidote.me, which today raised $11 million in a round led by Merck's strategic digital health fund. Existing investors Smedvig Capital and Octopus Ventures also participated in the round.
Antidote is run by a group of European tech executives, including Pablo Graiver, a former vice president of Kayak, and Eze Vidra, a general partner for Google's venture arm in Europe. The company is now based in New York City to help it expand more deeply into the United States.
It's a crowded market, but Antidote says it has a unique approach.
"Everyone is looking at a particular clinical trial and then trying to find the right patients," said Graiver, who had the idea of applying engagement models that work in other sectors, like e-commerce, to health care to bring a "matching tool to patients, rather than expecting them to come to us."
Antidote serves people who are already searching for information about a health condition with potentially relevant clinical trials. It works with groups such as JDRF, a research organization for Type 1 diabetes, and Lung Cancer Alliance, to add an Antidote-branded tool to their websites (here's an example).
Patients who are interested in participating in a clinical trial will be prompted to answer some questions, such as their location and how far they're willing to travel, their age, gender, and health condition(s). With each response, Antidote narrows down the list of trials they can apply for.
This approach is appealing to pharma companies, as the responses provide them with more information than they could glean from a patients' medical record. For instance, they might learn whether a potential recruit is looking to get pregnant in the coming months, which might disqualify them from participating in the trial.
Antidote says its tool has been used to match patients for 14,000 clinical trials to date.
It gets paid through referral fees from pharmaceutical companies, as well as licensing fees for the health organizations it works with. Graiver said the company generated low-digit millions in revenues last year alone.
Correction: The company incorrectly used the Boston dateline in its press release. It is based in New York.